Skip to content

Research Progress of Acupuncture in the Treatment for Benign Prostatic Hyperplasia

Research Progress of Acupuncture in the Treatment for Benign Prostatic Hyperplasia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000242
Enrollment
Unknown
Registered
2024-08-15
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hyperplasia

Interventions

control group:Oral sustained-release capsules of tamsulosin hydrochloride

Sponsors

Beijing Traditional Chinese Medicine Hospital Inner Mongolia Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1)It accords with the diagnosis of Western medicine and the syndrome differentiation standard of kidney-yang deficiency syndrome;2)Age 40-80 male standard;3)International Prostate Symptom Score (IPSS) > 5 and < 15;4)Course of disease =3 months;5)Stop using a1 blocker drugs for more than 1 month or 5a reductase inhibitors and Chinese medicine for more than 6 months;6)Maximum urine flow rate < 15 mL/s or average urine flow rate < 10mL/s;7)Willing to participate in this experiment, and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1)Prostate cancer, urinary calculi, urinary retention, and oliguria due to acute or chronic kidney failure;2)Upper urinary tract obstruction with hydrops and impaired renal function due to BPH;3)Gonorrhea, urinary infection caused by frequent urination;4)Upper urinary tract obstruction with hydrops and impaired renal function due to BPH;5)B ultrasound found obvious bladder diverticulum;6)Failure to receive invasive BPH therapy;7)Have a history of pelvic surgery or injury affect local organs, muscles, nerves and other functional status;8)Accompanied by liver, cardio-cerebrovascular and hematopoietic system and other serious primary diseases, or abdominal aortic aneurysm, liver and spleen abnormal enlargement;9)With cognitive impairment, mental disorders, unable to cooperate with the examination and treatment;10)Coagulopathy or long-term use of anticoagulants such as warfarin sodium, Dabigatran and other patients;11)Severe fear of needles or allergies to metal needles.

Design outcomes

Primary

MeasureTime frame
IPSS;

Secondary

MeasureTime frame
Number of nocturnal urination;prostate colored doppler ultrasoun;

Countries

China

Contacts

Public ContactCaolu

Beijing Traditional Chinese Medicine Hospital Inner Mongolia Hospital

957132854@qq.com13947856489

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026